2484919-71-1

2484919-71-1 structure

Name: RET-IN-19
Chemical Name: RET-IN-19
CAS Number: 2484919-71-1
Molecular Formula: C₂₈H₂₈N₆O₄S
Molecular Weight: 544.62
Catalog: Signaling Pathways Cell Cycle/DNA Damage Aurora Kinase
Create Date: 2022-10-12 15:41:35
Modify Date: 2025-08-22 00:21:11
RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].

Name	RET-IN-19

Description	RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].
Related Catalog	Signaling Pathways >> Epigenetics >> Aurora Kinase Signaling Pathways >> MAPK/ERK Pathway >> MAP4K Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Cell Cycle/DNA Damage >> Aurora Kinase Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Fms
Target	EGFR:56.78 ± 4. μM (IC50) Aurora A:0.242 ± 0. μM (IC50) Aurora B:0.536 ± 45 μM (IC50) MAP4K4:3.428 ± 0. μM (IC50)
In Vitro	RET-IN-19 (compound 59) shows growth inhibition of LC-2/ad cells which RET-CCDC6 driven, with a GI50 of 0.1067 ± 0.004 μM[1]. RET-IN-19 (3 μM) shows inhibition of LC-2/ad cells migration[1]. RET-IN-19 inhibits EGFR, Aurora A, Aurora B, Nek2, CSF-1R, MAP4K4, NIK, and RET, with IC50 values of 56.78 ± 4.94, 0.242 ± 0.036, 0.536 ± 45.12, >200, 1.65 ± 0.235, 3.428 ± 0.150, >10, and 0.0068 ± 0.0003, respectively[1].
References	[1]. Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691.

Molecular Formula	C₂₈H₂₈N₆O₄S
Molecular Weight	544.62